Key Highlights
Medicine · Diabetes
This correction article refines our understanding of how the SGLT2 inhibitor empagliflozin exerts cardioprotective effects following acute myocardial infarction through epigenetic mechanisms involving sirtuins and regulatory miRNAs. Researchers have elucidated specific molecular pathways by which empagliflozin modulates these epigenetic determinants to promote cardiac recovery, offering a mechanistic explanation for the drug’s clinical benefits beyond glycemic control. For a leading diabetologist focused on managing complex diabetes complications, this work provides critical insights into how empagliflozin may mitigate post-infarction damage, directly informing therapeutic strategies for patients with diabetes at high cardiovascular risk.
Novelty: 85%
Rigor: 92%
Significance: 88%
Validity: 90%
Clarity: 82%
Update Your Briefing Preferences
Stay curious. Stay informed —
Science Briefing
Your briefing is personalized based on your selected fields, keywords, and research interests.
